Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) priced its initial public offering in Hong Kong at the upper limit of its indicative range to raise HK$9.75 billion in net proceeds.
The Chinese drugmaker issued 224.5 million shares at HK$44.05 each, the top end of its guidance of as low as HK$41.45 per share, according to a Thursday filing with the Hong Kong Exchange.
The deal's Hong Kong public offering portion was 454.9 times subscribed, prompting the company to issue 48.3 million shares, a near fourfold increase from the 12.3 million shares initially allotted.
The international offering portion was 17.1 times subscribed, and the firm issued 176.2 million shares, lower than the initial allocation of 212.2 million.
The cornerstone investors, including Singaporean sovereign wealth fund GIC, subscribed to a total of 93.7 million IPO shares.
Hengrui Pharma starts trading on the Hong Kong bourse today, May 23.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。